Insulin regular versus tab repaglinid in patient with DM type 2

Insulin regular versus tab repaglinid in patient with DM type 2 that taking NPH l injection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201109177568N1

Enrollment

Registered

2012-03-12

Start date

2011-10-11

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus type 2. impaired glucose tolerance

Interventions

Intervention 1: Control group: Insulin regular up to achieve optimum level of glucose. Intervention 2: Repaglinide tab: 0.5mg/bd up to maximum dose of 2mg/bd.

Treatment - Drugs

Control group: Insulin regular up to achieve optimum level of glucose

Repaglinide tab: 0.5mg/bd up to maximum dose of 2mg/bd

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1) DM type 2 patients, 2) BMI>25 3) Receiving full doses of antihyperglycemic agents (Glibenclimide 10mg/daily, Metformin 1500mg/daily) 4) Uncontrolled patients (HbA1c>7.5, PPG>180mg/dl) Exclusion criteria: 1) Diabetes coma, 2) Recurrent or sever hypoglycemic attacks 3) End stage cardiovascular, liver and renal disease 4) Drug history included rifampin, carbamazepin, erythromycin, nifedipin, warfarin, glucocorticoid

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Postprandial glucose. Timepoint: Before intervention, 12weeks after intervention. Method of measurement: Glucometer.;FBS. Timepoint: Before intervention, 12weeks after intervention. Method of measurement: labratory.;4pm BS. Timepoint: Before intervention, 12weeks after intervention. Method of measurement: Glucometer.	—

Secondary

Measure	Time frame
HbA1C. Timepoint: Before intervention, 12weeks after intervention. Method of measurement: Affinity chromatography Boronate.;Peptide_c. Timepoint: Before intervention, 12weeks after intervention. Method of measurement: Electero chemy luminecance.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr mariam hajipour

Vali-e-asr Hospital, Zanajan University of medical science

hajipour@yahoo.com+91 11369772

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026